Last reviewed · How we verify
Purified Verocell Rabies Vaccine
This vaccine stimulates the immune system to produce antibodies and cellular immunity against rabies virus by presenting inactivated viral antigens.
This vaccine stimulates the immune system to produce antibodies and cellular immunity against rabies virus by presenting inactivated viral antigens. Used for Rabies post-exposure prophylaxis (PEP) in previously unvaccinated individuals, Rabies pre-exposure prophylaxis (PrEP) in high-risk populations, Rabies post-exposure prophylaxis in previously vaccinated individuals.
At a glance
| Generic name | Purified Verocell Rabies Vaccine |
|---|---|
| Also known as | PVRV, VERORAB |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | inactivated viral vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Purified Verocell Rabies Vaccine is an inactivated rabies vaccine produced in Vero cell culture. It contains rabies virus that has been inactivated (killed) and purified to trigger both humoral (antibody) and cell-mediated immune responses. Upon vaccination, the immune system recognizes the viral antigens and develops protective immunity against rabies virus infection.
Approved indications
- Rabies post-exposure prophylaxis (PEP) in previously unvaccinated individuals
- Rabies pre-exposure prophylaxis (PrEP) in high-risk populations
- Rabies post-exposure prophylaxis in previously vaccinated individuals
Common side effects
- Injection site reactions (pain, erythema, swelling)
- Headache
- Myalgia
- Fever
- Nausea
Key clinical trials
- Safety and Immunogenicity of Purified Verocell Rabies Vaccine PVRV Administered Intramuscularly and Intradermally (PHASE4)
- A Comparison of Safety and Immunogenicity of Rabies Pre Exposure Prophylaxis Regimen Between Gvt of India Approved and WHO Approved. (PHASE3)
- Immunogenicity and Safety of Verorab™ in Indian Population (PHASE4)
- Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Purified Verocell Rabies Vaccine CI brief — competitive landscape report
- Purified Verocell Rabies Vaccine updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI